Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 + SHR-A2102 in advanced solid tumors
NCT06955390Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HRS-4642 in solid tumor, sponsored by Henan Cancer Hospital. Primary endpoints: Dose Limited Toxicity and Objective Response Rate at 1 year. Planned start May 2025; status: not yet recruiting.
02
Drugs
HRS-4642
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06955390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06955390.